The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.

ABSTRACT: Patients with bone metastatic castration-resistant prostate cancer (mCRPC) might benefit from radium-223 (²²³Ra) combined with new-generation hormonal agents (NHAs) in terms of survival and quality of life (QoL). However, the safety of combination therapies remains unclear. Therefore, we aimed to perform a network meta-analysis by reviewing the literature about the combination of ²²³Ra with abiraterone acetate plus prednisone (AAP) or enzalutamide and to evaluate the safety of combination therapy in bone mCRPC patients. Ultimately, ten studies (2835 patients) were selected, including four randomized controlled trials (RCTs), five retrospective cohort studies, and one single-arm study. Overall, there was no difference in the incidence of fracture between the ^223</

SUBMITTER: Wang MH 

PROVIDER: S-EPMC10411251 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature